
Eagle Pharmaceuticals EGRX
Quarterly report 2023-Q2
added 08-08-2023
Eagle Pharmaceuticals DIO Ratio 2011-2026 | EGRX
Annual DIO Ratio Eagle Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 149 | 174 | 79.4 | 39.4 | 49 | 32.7 | 18.1 | 351 | 40.3 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 351 | 18.1 | 104 |
Quarterly DIO Ratio Eagle Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 234 | 242 | - | 266 | 178 | 84.7 | - | 146 | 87.5 | 80.7 | - | 84.4 | 71.5 | 140 | - | 49.4 | 33 | 71 | - | 87.9 | 53.8 | 84.8 | - | 97 | 52.4 | - | - | 24 | 21.8 | 55.6 | - | 366 | 410 | 125 | 63.6 | 52.1 | 72.8 | 16.9 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 410 | 16.9 | 116 |
DIO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
133 | - | 7.5 % | $ 6.35 M | ||
|
Alimera Sciences
ALIM
|
58.7 | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
459 | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
82.7 | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
48.9 | - | 0.86 % | $ 117 M | ||
|
Aurora Cannabis
ACB
|
1.35 K | $ 3.32 | 0.3 % | $ 86.3 M | ||
|
China Pharma Holdings
CPHI
|
168 | $ 0.57 | -9.62 % | $ 9.95 M | ||
|
Catalent
CTLT
|
71.9 | - | - | $ 11.5 B | ||
|
Athenex
ATNX
|
158 | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
366 | - | - | $ 2.06 B | ||
|
Cronos Group
CRON
|
221 | $ 2.58 | 2.38 % | $ 1.34 B | ||
|
DURECT Corporation
DRRX
|
460 | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
176 | $ 8.01 | -0.5 % | $ 410 M | ||
|
Endo International plc
ENDP
|
100 | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
995 | - | - | $ 36.6 M | ||
|
Pacira BioSciences
PCRX
|
246 | $ 23.2 | 2.43 % | $ 1.07 B | ||
|
HEXO Corp.
HEXO
|
703 | - | 2.45 % | $ 38.1 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
239 | $ 3.13 | 2.62 % | $ 44 M | ||
|
Bausch Health Companies
BHC
|
172 | $ 4.99 | -2.25 % | $ 1.82 B | ||
|
Perrigo Company plc
PRGO
|
148 | $ 9.64 | 0.73 % | $ 1.34 B | ||
|
Harrow Health
HROW
|
65.1 | $ 35.2 | 3.53 % | $ 1.29 B | ||
|
OptiNose
OPTN
|
370 | - | - | $ 1.08 B | ||
|
Evolus
EOLS
|
71.3 | $ 4.43 | -5.34 % | $ 286 M | ||
|
Rockwell Medical
RMTI
|
28.5 | $ 1.03 | 0.98 % | $ 24 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
117 | $ 2.34 | -8.24 % | $ 2.9 M | ||
|
Tilray
TLRY
|
170 | $ 6.66 | 3.26 % | $ 4.12 B | ||
|
OrganiGram Holdings
OGI
|
2.83 K | $ 1.34 | -1.47 % | $ 402 M | ||
|
PetIQ
PETQ
|
64.9 | - | 1.64 % | $ 400 M | ||
|
PLx Pharma
PLXP
|
97.2 | - | -27.8 % | $ 2.56 M | ||
|
ProPhase Labs
PRPH
|
30.1 | - | - | $ 5.07 M | ||
|
Veru
VERU
|
179 | $ 2.29 | -0.43 % | $ 309 M | ||
|
Jupiter Wellness
JUPW
|
59.7 | - | - | $ 33.6 M | ||
|
TherapeuticsMD
TXMD
|
1.04 K | $ 2.29 | -0.87 % | $ 23.9 M | ||
|
Viatris
VTRS
|
140 | $ 13.36 | 0.53 % | $ 16 B | ||
|
Radius Health
RDUS
|
204 | - | - | $ 1.42 B | ||
|
Lannett Company
LCI
|
127 | - | 1.15 % | $ 7.11 M | ||
|
cbdMD
YCBD
|
165 | $ 0.77 | 1.06 % | $ 3.32 M | ||
|
Organogenesis Holdings
ORGO
|
85.9 | $ 2.41 | -2.43 % | $ 317 M | ||
|
Canopy Growth Corporation
CGC
|
167 | $ 0.96 | -0.87 % | $ 103 M | ||
|
Assertio Holdings
ASRT
|
322 | $ 16.51 | 17.93 % | $ 106 M | ||
|
Recro Pharma
REPH
|
49.1 | - | -4.76 % | $ 65.3 M |